$11.20
0.030.27%
Last update: Nov 10, 6:34 PM
Intellia Therapeutics Inc
NTLANASDAQ
Intellia Therapeutics rose 19.0% from $10.18 to $12.11, ahead of the S&P 500's +9.8%. Its worst day was Apr 24 (−14.1%), and its low came Nov 20 at $8.04.
Nov 11, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Intellia Therapeutics closed at its lowest level of the year, 21.0% below where the year started.
−2.4% · S&P 500 −1.5%
Intellia Therapeutics shares rose 13.3%, while the S&P 500 rose 0.5%.
+13.3% · S&P 500 +0.5%
Story events cover the past 12 months · Times ET
EPS of $-0.83 beat the $-0.97 estimate on $23.0M revenue (est. $12.0M).
+6.4% · S&P 500 −0.6%
Intellia Therapeutics shares fell 14.1%, while the S&P 500 rose 0.8%.
−14.1%, the year's worst day · S&P 500 +0.8%
EPS of $-0.81 beat the $-0.90 estimate on $15.0M revenue (est. $14.2M).
+2.3% · S&P 500 +0.2%
Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published in the New
+23.2%, the year's best day · S&P 500 +1.8%
Intellia Therapeutics closed at its highest level of the year, 75.2% above where the year started.
+1.6% · S&P 500 +0.9%
EPS of $-0.80 beat the $-0.80 estimate on $7.7M revenue (est. $13.4M).
+2.5% · S&P 500 −0.2%
Intellia Therapeutics shares rose 14.5%, while the S&P 500 rose 0.2%.
+14.5% · S&P 500 +0.2%
EPS of $-0.91 missed the $-0.79 estimate on $7.2M revenue (est. $9.8M).
−9.8% · S&P 500 −4.4%
Where it ended: a close of $12.11 on Nov 9, 2026. Up next: Q4 2026 earnings on Feb 25, 2027 (EPS est. $-0.77, revenue est. $17.2M).
Nothing in the past 12 months.
All NTLA dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for NTLA and SPY from Benzinga historical bars. Not investment advice.
